Benefits From Small Molecule Administration as Compared With Abciximab Among Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Angioplasty. A Meta-Analysis

Journal of the American College of Cardiology

Volumn 53, Issue 18, 2009, Pages 1668-1673

  De Luca, Giuseppe ^a   Ucci, Grazia ^a   Cassetti, Ettore ^a   Marino, Paolo ^a  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

abciximab; meta analysis; primary angioplasty; small molecules; STEMI

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; TIROFIBAN;

ANGIOPLASTY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG MEGADOSE; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HEMOPERITONEUM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOPLASTY, BALLOON; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; FIBRINOLYTIC AGENTS; HEMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; ODDS RATIO; PEPTIDES; PLATELET AGGREGATION INHIBITORS; TYROSINE;

EID: 65249091961     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.01.053     Document Type: Article

References (15)

1. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 61 (2003) 13-20
2. De Luca G., van't Hof A.W., Ottervanger J.P., et al. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 150 (2005) 557-562
3. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
4. Montalescot G., Antoniucci D., Kastrati A., et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 28 (2007) 443-449
5. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354 (1999) 1896-1900
6. Ernst N.M., Suryapranata H., Miedema K., et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 44 (2004) 1187-1193
7. Danzi G.B., Sesana M., Capuano C., et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol 94 (2004) 35-39
8. Valgimigli M., Percoco G., Malagutti P., et al., STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
9. van Werkum J.W., Gerritsen W.B., Kelder J.C., et al. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial. Neth Heart J 15 (2007) 375-381
10. Valgimigli M., Campo G., Percoco G., et al., Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299 (2008) 1788-1799
11. Marzocchi A., Manari A., Piovaccari G., et al., FATA Investigators. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the Facilitated Angioplasty with Tirofiban or Abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J 29 (2008) 2972-2980
12. Zeymer U. Eptifibatide Versus Abciximab in primary PCI for Acute ST elevation Myocardial Infarction. EVA-AMI Trial. http://scientificsessions.americanheart. org/includes/pdfs/evaAmifinal.pdf Accessed November 30, 2007
13. Topol E.J., Moliterno D.J., Herrmann H.C., et al., TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344 (2001) 1888-1894
14. Moliterno D.J., Yakubov S.J., DiBattiste P.M., et al., TARGET Investigators. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 360 (2002) 355-360
15. De Luca G., Suryapranata H., Stone G.W., et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol 47 (2006) 685-686